Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus - PubMed

4 hours ago

Obinutuzumab, a glycoengineered type II anti-CD20 monoclonal antibody, is approved for active lupus nephritis but its efficacy and safety in systemic lupus erythematosus (SLE) were studied.
A phase 3, double-blind, placebo-controlled trial involved 303 adults with active SLE (excluding proliferative/membranous lupus nephritis) on standard therapy.
Patients received obinutuzumab (1000 mg) or placebo on day 1 and weeks 2, 24, and 26.
Primary endpoint at week 52 was SLE Responder Index 4 (SRI-4) response, showing 76.7% response in obinutuzumab vs. 53.5% in placebo (adjusted difference: 23.1 percentage points; P<0.001).
Obinutuzumab was superior to placebo in all key secondary endpoints, including BILAG-based response, sustained glucocorticoid reduction, and flare prevention.
Adverse events occurred in 88.7% (obinutuzumab) vs. 81.5% (placebo); serious adverse events in 15.9% vs. 11.9%.
One death in obinutuzumab group vs. three in placebo group during the double-blind period.
Obinutuzumab demonstrated superior efficacy over placebo in active SLE patients.

Hasty Briefsbeta